HomeAbout UsPlace your orderTechnologiesServicesNews/blogContact us

Available Technologies:
Current core technologies available commercially:

1. New catalysts for environmentally friendly synthetic transformations applicable to medicinal (small drug molecules) manufacturing.

CDS team has been involved in developing Green Chemistry catalysts applicable to pharmaceutical industry. Our most popular catalyst, MCAT- 53™ is a ruthenium based catalyst that is capable of C-H functionalization and coupling. MCAT-53™ has been independently developed through in-house efforts in our labs at Plainfield, Illinois through several years of work. 

Recently, a publication in Organic Process, Research and development, 2018, Vol 22, 2118-2130 provided many applications of this catalyst in cross-coupling reactions being performed in DI/distilled water under air- and ligand-free conditions. Synthesis of an advanced intermediate of CETP inhibitor, Anacetrapib, in water has been demonstrated to give a single regioisomer using the MCAT-53 catalyst. Read here the full publication, OPRD, V 22, 2118-2130.

We are very keen to see further development and widespread use go MCAT-53™ In pharmaceutical industry. We have adopted a very flexible approach to making these catalysts accessible and available for R&D. 

Salient feature of CDS catalyst MCAT-53™ is that it meets Green Chemistry Principles and is cheaper than existing alternatives. 

​Watch a short video of MCAT-53 technology:

2. Synthetic Metalloporphyrins for Metabolite identification and synthesis.

By using our synthetic metalloporphyrin technology, Phase 1 metabolites can be generated in high yield from your molecules. Our method will provide you with the rapid synthesis of metabolites that are identified in vivo and/or ex vivo. Molecularly diverse compounds can be produced that will assist you in your search for discovering new chemical entities (NCEs). 

This approach affords an efficient method for the systematic preparation and identification of the entire spectrum of metabolites from a chosen drug. We can envision the screening of a series of compounds by reacting them with different permutations of a metalloporphyrin, co-oxidant and a suitable solvent. Reaction conditions that produce the maximum number of metabolites can be defined. This logically leads to a subsequent scaled-up optimal process. The oxidation products can be separated and subjected to toxicologic, pathologic, histopathalogic, or genotoxic testing. More on this can be read here

The compounds resulting from the metalloprophyrin reaction will be isolated, identified and delivered according to customer requirements. 

Copyright ® Chicago Discovery Solutions. All Rights Reserved.